Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 513 of 1,261

  1. US 10221222

    Dermaseptin-type and piscidin-type antimicrobial peptides

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  2. US 10221223

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    The Regents of the University of California · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  3. US 10221226

    LEDGF peptides and formulations thereof for treatment of degenerative disorders

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  4. US 10221244

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  5. US 10220001

    Active self-healing biomaterial system

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  6. US 10220002

    Controlled-release peptide compositions and uses thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  7. US 10220029

    Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES” · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  8. US 10221408

    Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  9. US 10220117

    Methods of mammalian retinal stem cell production and applications

    The Regents of the University of California · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  10. US 10221174

    N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  11. US 10221164

    Cannabinergic nitrate esters and related analogs

    Northwestern University · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  12. US 10221235

    Endotrophin neutralization and use thereof

    The Board of Regents of the University of Texas System · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  13. US 10221414

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  14. US 10221243

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  15. US 10221455

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  16. US 10221195

    Pyridine compounds

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  17. US 10221161

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  18. US 10220093

    Long-acting semi-solid lipid formulations

    MIRA PHARMA CORPORATION · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  19. US 10220082

    WT1 vaccine

    Inovio Pharmaceuticals, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  20. US 10220078

    Methods of using thrombin derivatives to treat medulloblastoma

    The Board of Regents of the University of Texas System · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  21. US 10220046

    Compositions and methods for disease treatment using nanoparticle delivered compounds

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  22. US 10220070

    Alphaa-crystallin mimetic peptides and uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  23. US 10220042

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  24. US 10220020

    Polymer-des-ethyl sunitinib conjugates

    Nektar Therapeutics · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.